Pyrazolopyrimidine Kinase Inhibitors for Selective CDK Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds and treatments to effectively target cyclin-dependent kinases (CDKs) associated with various diseases such as cancer, inflammation, arthritis, neurodegenerative diseases, cardiovascular diseases, and viral diseases, as existing inhibitors have limitations in selectivity and efficacy.
Innovation Solution
Development of novel pyrazolo[1,5-a]pyrimidine compounds that act as protein kinase inhibitors, specifically targeting CDKs, which can be used in pharmaceutical compositions to treat and prevent proliferative diseases, including cancer, inflammation, and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors are used, then CDK activity is inhibited, but selectivity and efficacy are limited
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the pyrazolopyrimidine core structure. Different substituents (R1-R6) are placed at specific locations to optimize binding to particular CDK isoforms, thereby achieving selectivity while maintaining inhibitory efficacy through localized structural modifications rather than global changes to the entire molecule.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and molecular properties of the pyrazolopyrimidine compounds. By adjusting these chemical parameters, the invention optimizes both the selectivity (which CDK isoform is targeted) and efficacy (how strongly it inhibits that isoform) of the inhibitors across different disease contexts.
2Reliability
If new pyrazolopyrimidine compounds are developed, then CDK inhibition efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent applies universality by designing a core pyrazolopyrimidine structure that serves as a universal scaffold for multiple CDK inhibitors. This core structure provides common essential features for CDK binding, while allowing diverse substituents to be attached, enabling the same basic framework to target different CDK isoforms with varying selectivity and efficacy profiles.
Solution Approach 2:
The patent uses segmentation by dividing the inhibitor molecule into distinct functional segments: a core pyrazolopyrimidine structure and separate substituent groups (R1-R6). This segmentation allows independent optimization of each segment's properties, managing overall molecular complexity by treating the molecule as composed of modular, independently designable units with specific functions.
Data Source
AI summary
The present invention relates to Pyrazolo [1,5-a]pyrimidine compounds of formula III usefu as protein kinase inhibitors, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases (Formula III), wherein : R is an aryl substituted with one or more heteroaryl; R2 is selected from the group consisting of R9, alkyl, alkynyl, alkynylalkyl, cycloalkyl, -CF3, -C(O2)R6, aryl, arylalkyl, heteroarylalkyl, heterocyclyl, alkyl substituted with 1-6 R9 groups which groups can be the same or different with each R9 being independently selected, aryl substituted with 1-3 aryl or heteroaryl groups which can be the same or different and are independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups, (a), (b), (c) and (d), and heteroaryl substituted with 0-3 aryl or heteroaryl groups which can be the same or different and are independently selected from alkyl, phenyl, pyridyl, thiophenyl, furapyl and thiazolo groups; R3 is selected from the group consisting of H, halogen, -NR5R6, -C(O)NR5R6, alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl, etc; R4 is H halo or alkyl.